Study on host immune response during treatment of patients with pulmonary nontuberculous mycobacterial disease - PNTM study

Department of Respiratory Medicine, University of Tsukuba0 个研究点目标入组 100 人开始时间: 2022年12月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Comorbid respiratory disease: presence of any existing clinically significant known respiratory disease other than pulmonary NTM disease. 2. Malignancy: current malignancy or history of cancer that has just gone into remission less than 12 months prior to entry. 3. Liver disease: known pre-existing unstable liver disease. 4. Cardiovascular: Patients with severe or clinically significant cardiovascular disease that cannot be controlled with standard therapy. 5. Other co-morbidities: patients with known clinically significant endocrine, autoimmune, metabolic, neurologic, renal, gastrointestinal, hepatic, or hematologic disease that cannot be controlled with standard therapy. patients receiving systemic steroids for more than 4 weeks. However, patients receiving prednisolone equivalent of 10 mg/day or less of steroids will be subject to observation. 6. Pregnancy: subjects who are pregnant or lactating.

发起方

Department of Respiratory Medicine, University of Tsukuba